Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
SUGT1 CRISPR/Cas9 KO Plasmid (h): sc-405128
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- SUGT1 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the SUGT1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: SUGT1 Antibody (B-10): sc-398625
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
SUGT1 CRISPR/Cas9 KO Plasmid (h) | sc-405128 | 20 µg | $397.00 |
Overview
SUGT1 (suppressor of G2 allele of SKP1 homolog) is a conserved co-chaperone that interfaces with HSP90 and participates in assembly and stability of multi-protein complexes central to cell cycle progression. It has been implicated in kinetochore function and mitotic checkpoint control, supporting accurate chromosome segregation and proliferation. SUGT1 also contributes to innate immune signaling by modulating NOD1/NOD2-dependent pathways and downstream inflammatory responses through regulated protein complex formation. Dysregulated SUGT1 expression or function has been associated with altered proteostasis, cell cycle defects, and inflammatory phenotypes relevant to cancer biology and immune-related disorders in human model systems.
SUGT1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the SUGT1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the SUGT1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the SUGT1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish SUGT1 protein expression.
This CRISPR knockout system enables efficient generation of SUGT1-deficient cell models for investigation of SUGT1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting SUGT1 exon(s) critical for SUGT1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple SUGT1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by SUGT1 CRISPR/Cas9 KO Plasmid (h) and SUGT1 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the SUGT1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by SUGT1 HDR Plasmid (h) and SUGT1 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by SUGT1 homology arms to support homology-directed repair at defined SUGT1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.